Suppr超能文献

造血干细胞移植:生物伦理学视角

Hematopoietic Stem Cell Transplantation: A Bioethical Lens.

作者信息

Liso Arcangelo, Neri Margherita, Maglietta Francesca, La Russa Raffaele, Turillazzi Emanuela

机构信息

Institute of Hematology, Department of Medical and Surgical Sciences, University of Foggia, Viale Pinto 1, 71122 Foggia, Italy.

Department of Morphology, Experimental Medicine and Surgery, University of Ferrara, Via Fossato di Mortara 70, 44121 Ferrara, Italy.

出版信息

Stem Cells Int. 2017;2017:1286246. doi: 10.1155/2017/1286246. Epub 2017 Jun 27.

Abstract

Hematopoietic stem cell transplantation (HSCT) is one of a range of therapeutic options available to patients suffering from various diseases. HSCT procedure involves important ethical and legal aspects that can occur at every phase of the procedure: the clinical choice of whether to perform the procedure, pretransplantation preparation regimens, donor selection, stem cell harvest procedure, transplantation phase, and short-term and long-term follow-up care. In this discussion paper, we outline the ethical issue-facing physicians involved in HSCT. Currently, HSCT is a widely accepted treatment for many life-threatening diseases. It thus represents a real therapeutic hope for many patients. It does, however, carry a burden of possible morbidity and mortality. Consequently, there are substantial information and communication issues involved in the consent process for HSCT. In the final decision, the judgements of different parties, such as patients, family members, and healthcare professionals, intersect and overlap and this is particularly true when the patient is a minor. Finally, HSCT is a very expensive procedure. The social and economic concerns of HSCT are discussed within the actual contextual framework of the dramatic increase in healthcare costs and inequalities in healthcare in relation to socioeconomic status, educational status, and ethnicity.

摘要

造血干细胞移植(HSCT)是患有各种疾病的患者可采用的一系列治疗选择之一。HSCT程序涉及该程序每个阶段可能出现的重要伦理和法律问题:是否进行该程序的临床选择、移植前准备方案、供体选择、干细胞采集程序、移植阶段以及短期和长期随访护理。在本讨论文件中,我们概述了参与HSCT的医生所面临的伦理问题。目前,HSCT是许多危及生命疾病的广泛接受的治疗方法。因此,它对许多患者来说代表着真正的治疗希望。然而,它确实带来了可能的发病和死亡负担。因此,HSCT的同意过程涉及大量信息和沟通问题。在最终决定中,不同方(如患者、家庭成员和医疗保健专业人员)的判断相互交叉和重叠,当患者是未成年人时尤其如此。最后,HSCT是一个非常昂贵的程序。在医疗保健成本急剧增加以及医疗保健在社会经济地位、教育状况和种族方面存在不平等的实际背景框架内,讨论了HSCT的社会和经济问题。

相似文献

1
Hematopoietic Stem Cell Transplantation: A Bioethical Lens.
Stem Cells Int. 2017;2017:1286246. doi: 10.1155/2017/1286246. Epub 2017 Jun 27.
2
Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency Diseases: Current Status and Future Perspectives.
Front Pediatr. 2019 Aug 8;7:295. doi: 10.3389/fped.2019.00295. eCollection 2019.
4
Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation.
Expert Opin Biol Ther. 2016 Nov;16(11):1361-1372. doi: 10.1080/14712598.2016.1229773. Epub 2016 Sep 2.
6
Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.
Leuk Lymphoma. 2018 May;59(5):1133-1142. doi: 10.1080/10428194.2017.1375100. Epub 2017 Sep 21.
7
Experiences and Decision Making in Hematopoietic Stem Cell Transplant in Sickle Cell Disease: Patients' and Caregivers' Perspectives.
Biol Blood Marrow Transplant. 2018 May;24(5):1041-1048. doi: 10.1016/j.bbmt.2017.11.018. Epub 2017 Nov 28.
8
Procedures and methods of benefit assessments for medicines in Germany.
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
9
Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner.
Swiss Med Wkly. 2012 Oct 15;142:w13696. doi: 10.4414/smw.2012.13696. eCollection 2012.

引用本文的文献

1
Stem Cell-Based Cancer Therapies: A Commentary on Therapeutic Promise, Health Impacts and Translational Barriers.
Cancer Innov. 2025 Sep 8;4(5):e70025. doi: 10.1002/cai2.70025. eCollection 2025 Oct.
3
Bone marrow transplant: A two-decade single centre hematology experience.
Med J Armed Forces India. 2023 Nov-Dec;79(6):657-664. doi: 10.1016/j.mjafi.2023.09.005. Epub 2023 Sep 13.
4
Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies.
Curr Oncol Rep. 2022 Jan;24(1):125-133. doi: 10.1007/s11912-022-01194-3. Epub 2022 Jan 21.
6
Immigrants as donors and transplant recipients: specific considerations.
Intensive Care Med. 2019 Mar;45(3):401-403. doi: 10.1007/s00134-019-05534-z. Epub 2019 Jan 30.
7
Stem Cell Research and Clinical Translation: A Roadmap about Good Clinical Practice and Patient Care.
Stem Cells Int. 2017;2017:5080259. doi: 10.1155/2017/5080259. Epub 2017 Sep 27.

本文引用的文献

1
Latin America: the next region for haematopoietic transplant progress.
Bone Marrow Transplant. 2017 May;52(5):798. doi: 10.1038/bmt.2017.48.
2
Awareness of cord blood collection and the impact on banking.
Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26412. Epub 2017 Jan 23.
3
Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview.
Cancer Res. 2016 Nov 15;76(22):6445-6451. doi: 10.1158/0008-5472.CAN-16-1311. Epub 2016 Oct 26.
4
Haematopoietic stem cell transplantation survivorship and quality of life: is it a small world after all?
Support Care Cancer. 2017 Feb;25(2):421-427. doi: 10.1007/s00520-016-3418-5. Epub 2016 Oct 3.
7
Informed Consent in Decision-Making in Pediatric Practice.
Pediatrics. 2016 Aug;138(2). doi: 10.1542/peds.2016-1485.
8
Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation: Stem Cell Donation Behaviors.
Biol Blood Marrow Transplant. 2016 Sep;22(9):1710-1716. doi: 10.1016/j.bbmt.2016.06.014. Epub 2016 Jun 22.
9
Cancer treatment and survivorship statistics, 2016.
CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.
10
Alternative donors: cord blood for adults.
Semin Hematol. 2016 Apr;53(2):65-73. doi: 10.1053/j.seminhematol.2016.01.006. Epub 2016 Jan 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验